Roivant Sciences Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ROIV | 6IB.F | 9995.HK | 9969.HK | 0A3M.IL | ARGX | |
|---|---|---|---|---|---|---|
| Market cap | 27.61B | 17.27B | 40.23B | 21.56B | 25.17B | 58.57B |
| P/E (TTM) | — | 123.8 | 6.1 | 20.3 | 5.1 | 32.3 |
| Forward P/E | -27.5 | — | 46.7 | 53.2 | 5.1 | 28.0 |
| Price/book | 6.5 | 6.2 | 3.8 | 1.9 | 1.1 | 173.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +85.85% | −1.76% | −19.94% | −14.61% | −13.17% | +9.44% |
| Today | +6.08% | +3.42% | +1.49% | +1.33% | +2.81% | +3.36% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ROIV news ›Imaging trends in pediatric uveitis
OCT methods are invaluable in the assessment of patients with the condition. Reviewed by Debra Goldstein, MD, FRCSC A number of imaging modalities may aid in the identification and management of uveitis, according to Debra Goldstein,…
OT Roundup: 3 FDA approvals, vorolanib insert miss, brepocitinib in uveitis
Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME. This edition of OT Roundup covers 3 FDA approvals announced on a single day, a second phase 3 miss for…
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
Oct 01, 2026, 10:00 ET NORTH CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in…
Roivant Sciences Ltd. $ROIV Position Trimmed by Inspire Investing LLC
Posted by Defense World Staff on Oct 26th, 2026 ROIV opened at $36.49 on Monday. The firm has a market cap of $26.36 billion, a price-to-earnings ratio of -68.85 and a beta of 1.10. Roivant Sciences Ltd. has a 12 month low of $17.89 and a…
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow
2026-10-24. The following slide deck was published by Roivant Sciences Ltd. The following slide deck was published by Roivant Sciences Ltd. in conjunction with this event.
Analyzing Verastem (NASDAQ:VSTM) and Roivant Sciences (NASDAQ:ROIV)
Posted by Defense World Staff on Oct 25th, 2026 Verastem (NASDAQ:VSTM – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
More from 1 other outlet
Roivant Sciences climbs on positive uveitis trial data
Roivant Sciences stock rose 6.8% in morning trading on Wednesday after the company and its subsidiary Priovant Therapeutics reported that brepocitinib met all primary and key secondary endpoints in two Phase 3 trials for non-infectious…
Roivant Sciences (ROIV) Jumps 6.2% to $37.10
AlphaStreet AlphaStreet Newsdesk powered by AlphaStreet Intelligence Roivant Sciences soared Wednesday, climbing 6.2% to $37.10 as investors cheered positive clinical trial results for a uveitis treatment. The biotechnology company’s…
Roivant, continuing ascent, claims another victory for rare disease drug
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for a form of uveitis, one analyst said. The new results offer another win for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net3
- seekingalpha.com3
- themarketsdaily.com3
- cnbc.com1
- news.alphastreet.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.